Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 5;11(5):627. doi: 10.3390/cancers11050627

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

DFX117 inhibit Met kinase activity. (A) Phospho- receptor tyrosine kinase (RTK) antibody array after DFX117 treatment. Phosphorylated RTKs were measured with the Human Phospho-RTK Array Kit (ARY001B) from R&D Systems according to the manufacturer’s instructions. A total of 250 μg of lysates from the A549 cells treated with 0.2 μM DFX117 were subjected to analysis. (B) Molecular docking model of DFX117 and Met. (C) Met kinase activity assay. The effect of DFX117 on Met kinase assay was measured by Met Kinase Assay/Inhibitor Screening Kit according to the manufacturer’s instructions (# KA0055, Abnova, Taipei, Taiwan). (D,E) DFX117 suppressed hepatocyte growth factor (HGF)/Met signaling pathway. Cells were treated with the indicated concentrations of DFX117 for 24 h.